and water, and also via vasodilatory effects. Importantly, it has also been shown that sacubitril/valsartan reduces the mortality for patients with chronic heart failure ( 3 ). Several other hormones, for instance glucagon-like peptide-1 (GLP-1) and
Search Results
Ulrik Ø Andersen, Dijana Terzic, Nicolai Jacob Wewer Albrechtsen, Peter Dall Mark, Peter Plomgaard, Jens F Rehfeld, Finn Gustafsson, and Jens P Goetze
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, and Sunitha Jothydev
, thiazolidinediones (TZDs), gliptins, GLP-1 analogs or gliflozins may be employed ( 21 ). The use of these traditional agents may be limited, however, because of several factors. Biguanides and TZDs improve the insulin resistance, but do not address the progressive
Marie Reeberg Sass, Nicolai Jacob Wewer Albrechtsen, Jens Pedersen, Kristine Juul Hare, Nis Borbye-Lorenzen, Katalin Kiss, Tina Vilsbøll, Filip Krag Knop, Steen Seier Poulsen, Niklas Rye Jørgensen, Jens Juul Holst, Cathrine Ørskov, and Bolette Hartmann
/Hitachi Modular analytics, Roche Diagnostic) as previously reported ( 7 ). The detection limit for each assay is <2 pmol/L, and intra-assay coefficients of variation are 1.9% (insulin) and 4.6% (C-peptide) ( 8 ). Previously published data on GIP, glucagon, GLP-1
Espen Nordheim and Trond Geir Jenssen
beneficial effects in patients with kidney disease beyond the blood-glucose lowering effect: receptor agonists of the glucagon-like protein 1 receptor (GLP-1 RA) and inhibitors of sodium-glucose-co-transporter-2 (SGLT2i). In secondary analyses of the SAVOR
Meena Asmar, Ali Asmar, Lene Simonsen, Flemming Dela, Jens Juul Holst, and Jens Bülow
indicate that GIP receptor expression in subcutaneous adipose tissue is inversely associated with BMI ( 35 , 36 ). Interestingly, the other incretin hormone, glucagon-like-peptide-1 (GLP-1), also increases total blood flow in adipose tissue in healthy
Wenrui Wang and Chuan Zhang
; Peptide (GLP-1) Similar developmental background to β-cells in vivo ; Large proportion and flexible plasticity; Share quantity of transcription factors; Corresponding metabolic mechanism and hormone secretion Low conversion rate; Weak proliferative
Peter Wolf, Alexandre Dormoy, Luigi Maione, Sylvie Salenave, Jacques Young, Peter Kamenický, and Philippe Chanson
development of hyperglycemia in 8 patients (23.5%). In two patients (14%), diabetes was treated by a s.c. injection of glucagon-like-peptide-1 (GLP-1) analog, and three patients (21%) received insulin. All other patients were treated by oral antidiabetic
Ann-Kristin Picke, Graeme Campbell, Nicola Napoli, Lorenz C Hofbauer, and Martina Rauner
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two gastrointestinal hormones known as incretins, ‘INtestine SeCRETion Insulin’, secreted in response to nutrient intake. In order to compensate for low incretin
Sakina H Bharmal, Wandia Kimita, Juyeon Ko, and Maxim S Petrov
centrifuged at 4000 g for5.5 min at 4°C, plasma separated, aliquoted, and stored at −80°C for future analyses.Amylin, C-peptide, glucagon, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), insulin, pancreatic polypeptide, and
Ivar Følling, Anna B Wennerstrøm, Tor J Eide, and Hilde Loge Nilsen
stimulation of glucagon-like peptide 1 receptors (GLP1R). GLP1R expression/protein has been found on phaeochromocytoma cells ( 42 ) and tumours ( 43 ), but whether they function normally or if they are expressed on cells positive for anti-insulin staining is
